HK1057182A1 - 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-1,5-a-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands - Google Patents

4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-1,5-a-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Info

Publication number
HK1057182A1
HK1057182A1 HK04100028A HK04100028A HK1057182A1 HK 1057182 A1 HK1057182 A1 HK 1057182A1 HK 04100028 A HK04100028 A HK 04100028A HK 04100028 A HK04100028 A HK 04100028A HK 1057182 A1 HK1057182 A1 HK 1057182A1
Authority
HK
Hong Kong
Prior art keywords
methoxypyrid
pyrazolo
butylamino
enantiomers
triazine
Prior art date
Application number
HK04100028A
Other languages
English (en)
Inventor
Paul J Gilligan
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of HK1057182A1 publication Critical patent/HK1057182A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
HK04100028A 2001-03-13 2004-01-02 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-1,5-a-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands HK1057182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27540301P 2001-03-13 2001-03-13
PCT/US2002/006837 WO2002072202A1 (en) 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Publications (1)

Publication Number Publication Date
HK1057182A1 true HK1057182A1 (en) 2004-03-19

Family

ID=23052141

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100028A HK1057182A1 (en) 2001-03-13 2004-01-02 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-1,5-a-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Country Status (36)

Country Link
US (4) US20030125330A1 (pt)
EP (1) EP1368094B1 (pt)
JP (1) JP4549630B2 (pt)
KR (1) KR100875595B1 (pt)
CN (1) CN100427093C (pt)
AR (1) AR032986A1 (pt)
AT (1) ATE355102T1 (pt)
AU (1) AU2002245605B2 (pt)
BG (1) BG66331B1 (pt)
BR (1) BR0208357A (pt)
CA (1) CA2440553C (pt)
CY (1) CY1106607T1 (pt)
CZ (1) CZ20032481A3 (pt)
DE (1) DE60218434T2 (pt)
DK (1) DK1368094T3 (pt)
EE (1) EE05433B1 (pt)
ES (1) ES2282401T3 (pt)
GE (1) GEP20053608B (pt)
HK (1) HK1057182A1 (pt)
HR (1) HRP20030822B1 (pt)
HU (1) HU229317B1 (pt)
IL (2) IL157615A0 (pt)
IS (1) IS2839B (pt)
MX (1) MXPA03008185A (pt)
MY (1) MY146935A (pt)
NO (1) NO328580B1 (pt)
NZ (1) NZ528207A (pt)
PL (1) PL208278B1 (pt)
PT (1) PT1368094E (pt)
RS (1) RS50863B (pt)
RU (1) RU2292347C2 (pt)
SK (1) SK287603B6 (pt)
TW (1) TWI257388B (pt)
UA (1) UA74634C2 (pt)
WO (1) WO2002072202A1 (pt)
ZA (1) ZA200306995B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094782B1 (en) * 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
BR0208357A (pt) * 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) * 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
CA2520805A1 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7153961B2 (en) 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7208596B2 (en) * 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
UA96458C2 (ru) * 2006-09-20 2011-11-10 Эли Лилли Энд Компани Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR102079844B1 (ko) * 2016-09-20 2020-02-20 가톨릭대학교 산학협력단 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
AU2018317398A1 (en) 2017-08-14 2019-11-21 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
MX2023001688A (es) 2020-08-12 2023-02-22 Spruce Biosciences Inc Metodos y composiciones para tratar el sindrome de ovario poliquistico.
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CA2249598A1 (en) 1996-03-26 1997-10-02 Paul Joseph Gilligan Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU3064397A (en) 1996-05-24 1997-12-09 Dow Chemical Company, The Process for preparing aliphatic ester compounds and alkanols
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
CA2259583C (en) * 1996-07-24 2009-11-17 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
CN1227554A (zh) * 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
WO1999001439A1 (en) 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
UA62972C2 (en) 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
IL134748A0 (en) 1997-09-02 2001-04-30 Du Pont Pharm Co Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
CA2314613C (en) * 1998-01-28 2009-12-08 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
AU3213699A (en) 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
BR0208357A (pt) * 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto

Also Published As

Publication number Publication date
NO20034023L (no) 2003-09-11
NO20034023D0 (no) 2003-09-11
MY146935A (en) 2012-10-15
BG108189A (bg) 2004-09-30
EE200300435A (et) 2003-12-15
HUP0303480A3 (en) 2005-12-28
KR100875595B1 (ko) 2008-12-23
HRP20030822A2 (en) 2004-04-30
IS6947A (is) 2003-09-10
DK1368094T3 (da) 2007-07-02
IL157615A0 (en) 2004-03-28
GEP20053608B (en) 2005-09-12
YU71503A (sh) 2006-05-25
CN1509196A (zh) 2004-06-30
US7662817B2 (en) 2010-02-16
NZ528207A (en) 2006-02-24
US20040014760A1 (en) 2004-01-22
JP4549630B2 (ja) 2010-09-22
HUP0303480A2 (hu) 2004-01-28
HU229317B1 (en) 2013-10-28
US20070054913A1 (en) 2007-03-08
CA2440553C (en) 2010-06-08
EE05433B1 (et) 2011-06-15
RS50863B (sr) 2010-08-31
PL368644A1 (en) 2005-04-04
UA74634C2 (uk) 2006-01-16
RU2003130093A (ru) 2005-03-20
AR032986A1 (es) 2003-12-03
AU2002245605B2 (en) 2006-02-02
DE60218434D1 (en) 2007-04-12
CZ20032481A3 (cs) 2007-12-27
MXPA03008185A (es) 2004-01-29
BG66331B1 (bg) 2013-06-28
US20030125330A1 (en) 2003-07-03
CA2440553A1 (en) 2002-09-19
IS2839B (is) 2013-06-15
EP1368094A4 (en) 2004-03-31
TWI257388B (en) 2006-07-01
DE60218434T2 (de) 2007-11-08
RU2292347C2 (ru) 2007-01-27
PT1368094E (pt) 2007-05-31
PL208278B1 (pl) 2011-04-29
KR20030080086A (ko) 2003-10-10
HRP20030822B1 (en) 2008-01-31
SK11572003A3 (sk) 2004-02-03
ATE355102T1 (de) 2006-03-15
CY1106607T1 (el) 2012-01-25
EP1368094A1 (en) 2003-12-10
ZA200306995B (en) 2004-09-08
EP1368094B1 (en) 2007-02-28
SK287603B6 (sk) 2011-03-04
WO2002072202A1 (en) 2002-09-19
BR0208357A (pt) 2004-06-29
US7358252B2 (en) 2008-04-15
CN100427093C (zh) 2008-10-22
US7157578B2 (en) 2007-01-02
IL157615A (en) 2009-09-01
NO328580B1 (no) 2010-03-22
ES2282401T3 (es) 2007-10-16
JP2004530662A (ja) 2004-10-07
US20080139567A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
HK1057182A1 (en) 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-1,5-a-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
DE60121294D1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
EE200200201A (et) Trüosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine.
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
PL366577A1 (en) Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
IL158697A0 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
HUP0401335A3 (en) Herbicidal pyridylpropynyloxyphenyl derivatives, preparation and use thereof
MXPA03000873A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
HK1075045A1 (en) 1,3,5-Triazine derivatives as ligands for human adenosine-a3 receptors
ITRM20010048A0 (it) Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute.
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
IT1317288B1 (it) Struttura di tavola, particolarmente per ponteggi, scaffalature,soppalchi e simili.
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof
ZA200400194B (en) Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists.
AU2002240578A1 (en) A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
AU2002346927A1 (en) 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
FR2820135B1 (fr) Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation
AU2002237294A1 (en) Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
MXPA03008588A (es) Nuevos derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos.

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE PRIORITY APPLICATION NO. FROM 275403 TO 275403 P.

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170306